In the case of 5-ASA, which is an anti-inflammatory drug known to inhibit the production of cytokines via peroxisome proliferator-activated receptor-gamma (PPAR-gamma) (394), over half of IBD patients fail to respond to this treatment, or lose response over time (395, 396). The gene discussed is PPARG; the disease is inflammatory bowel disease.